Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to:
Each site will invite all eligible patients to participate. Patients will be followed for up to 5 years or until patient withdrawal of consent, loss to follow-up, death, or the end of the study, whichever comes first.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with ATTR-CM | Patients with ATTR-CM. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| New York Heart Association (NYHA) Class | The NYHA functional classification categorizes the severity of heart failure. Patients are classified in 1 of 4 categories based on their physical limitations, as follows:
| From time of ATTR-CM diagnosis up to 5 years |
| Outpatient Diuretic Intensification | The clinician-reported outcome of ODI, which measures any post-diagnosis initiation or increase in the dose of loop diuretics, may help identify patients with ATTR-CM who are at an increased risk for adverse outcomes. ODI, a marker to monitor disease progression and/or worsening heart failure, is associated with a higher risk of all-cause mortality, cardiovascular hospitalizations, and urgent heart failure visits. Clinicians monitor ODI to help manage patients with ATTR-CM. | From time of enrollment for up to 5 years |
| Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score | Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life). | From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years |
| Kansas City Cardiomyopathy Questionnaire (KCCQ) | The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS] scores). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population will include adult patients with ATTR-CM who, at enrollment, are either initiating treatment with vutrisiran or are initiating treatment with another approved ATTR-CM therapy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trial Information Line | Contact | 1-877-ALNYLAM | clinicaltrials@alnylam.com | |
| Clinical Trial Information Line | Contact | 1-877-256-9526 | clinicaltrials@alnylam.com |
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Alnylam Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Trial Site | Recruiting | Naples | Florida | 34102 | United States | |
| Clinical Trial Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000686 | Amyloidosis |
| D009202 | Cardiomyopathies |
| ID | Term |
|---|---|
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006331 | Heart Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years |
| Patient Global Impressions - Change (PGI-C) | The PGI-C is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse." | From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years |
| Patient Global Impressions - Severity (PGI-S); | The PGI-S is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse." | From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years |
| Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9) | TSQM-9 is a 9-item general instrument that measures the major dimensions of satisfaction with a medication. The questionnaire consists of 3 domains: effectiveness, convenience and side effects. The scores of each domain range from 0 to 100 with higher scores representing higher satisfaction on that domain. | From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years |
| Recruiting |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| Clinical Trial Site | Recruiting | New Brunswick | New Jersey | 08901 | United States |
| Clinical Trial Site | Recruiting | Memphis | Tennessee | 38120 | United States |
| D002318 | Cardiovascular Diseases |